Compositions and methods for WT1 specific immunotherapy

Details Compositions and methods for WT1 specific immunotherapy Compositions and methods for WT1 specific immunotherapy

2011-03-29

2011-03-29

Schwadron, Ron (Department: 1644)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C514S04400A, C536S023400, C536S023500, C435S320100, C435S325000, C435S252300, C435S254110, C435S252330

Reexamination Certificate

active

07915393

ABSTRACT:
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

REFERENCES:
patent: 5350840 (1994-09-01), Call et al.
patent: 5622835 (1997-04-01), Herlyn et al.
patent: 5633142 (1997-05-01), Herlyn et al.
patent: 5670317 (1997-09-01), Ladanyi et al.
patent: 5679356 (1997-10-01), Bonnem et al.
patent: 5693522 (1997-12-01), Chada et al.
patent: 5726288 (1998-03-01), Call et al.
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 6096313 (2000-08-01), Jäger et al.
patent: 6277832 (2001-08-01), Sugiyama et al.
patent: 6316599 (2001-11-01), Call et al.
patent: 6818751 (2004-11-01), Xu et al.
patent: 7063854 (2006-06-01), Gaiger et al.
patent: 7115272 (2006-10-01), Gaiger et al.
patent: 7144581 (2006-12-01), Gaiger et al.
patent: 7316924 (2008-01-01), Bron et al.
patent: 7329410 (2008-02-01), Gaiger et al.
patent: 2003/0039635 (2003-02-01), Gaiger et al.
patent: 2003/0072767 (2003-04-01), Gaiger et al.
patent: 1004319 (2000-05-01), None
patent: 1103564 (2001-05-01), None
patent: 06-128299 (1994-05-01), None
patent: 11-89596 (1999-04-01), None
patent: 11-89599 (1999-04-01), None
patent: WO 91/07509 (1991-05-01), None
patent: WO 94/21287 (1994-09-01), None
patent: WO95/06725 (1995-03-01), None
patent: WO95/29995 (1995-11-01), None
patent: WO 96/38176 (1996-12-01), None
patent: WO 99/03506 (1999-01-01), None
patent: 99/51753 (1999-10-01), None
patent: WO99/58135 (1999-11-01), None
patent: WO 00/06602 (2000-02-01), None
patent: WO 00/18795 (2000-04-01), None
patent: WO 00/26249 (2000-05-01), None
patent: WO 01/25273 (2001-04-01), None
patent: WO 01/60970 (2001-08-01), None
patent: WO 01/62920 (2001-08-01), None
patent: WO 01/72786 (2001-10-01), None
patent: WO 01/94629 (2001-12-01), None
patent: WO 02/00677 (2002-01-01), None
patent: WO 02/28414 (2002-04-01), None
patent: WO 03/037060 (2003-05-01), None
Aaronson and Todaro, “Development of 3t3-like lines from Balb/c mouse embryo cultures: transformation susceptibility to SV40,”J. Cell. Physiol. 72(2):141-148, Oct. 1968.
Adachi et al., “Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1),”Oncogene13: 2197-2203, 1996.
Algar et al., “A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines,”Oncogene12: 1005-1014, 1996.
Altman et al., “Phenotypic analysis of antigen-specific T lymphocytes,”Science274:94-96, Oct. 4, 1996.
Appel, R.D. et al., “A new generation of information retrieval tools for biologists: the example of the ExPASy WWW server,”Trends in Biochemical Sciences19(6): 258-260, Jun. 1994.
Armstrong et al., “The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo,”Mechanisms of Development40: 85-97, 1992.
Bellantuono et al., “Selective elimination of leukemic progenitors by allorestricted CTL specific for WILMS Tumor Antigen-1 (WT-1),”Blood, 94(10):532A-533A, Nov. 15, 1999.
Bergmann et al., “High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome,”Blood90(3): 1217-1225, 1997.
Bergmann et al., “Wilms Tumor Gene Expression in Acute Myeloid Leukemias,”Leukemia and Lymphoma25: 435-443, 1997.
Blaudeck, N. et al., “Specificity of Signal Peptide Recognition in Tat-Dependent Bacterial Protein Translocation,”Journal of Bacteriology183(2): 604-610, Jan. 2001.
Boon, T., “Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy,”Int. J. Cancer54: 177-180, 1993.
Brenner et al., “RNA polymerase chain reaction detects different levels of four alternatively splicedWT1transcripts in Wilms' tumors,”Oncogene7: 1431-1433, 1992.
Brieger et al., “The Expression of the Wilms' Tumor Gene in Acute Myelocytic Leukemias as Possible Marker for Leukemic Blast Cells,”Leukemia8(12): 2138-2143, 1994.
Brieger et al., “The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR,”Annals of Oncology6: 811-816, 1995.
Buckler et al., “Isolation, Characterization, and Expression of the Murine Wilms' Tumor Gene (WT1) During Kidney Development,”Molecular and Cellular Biology11: 1707-1712, 1991.
Call et al., “Isolation and Characterization of a Zinc Finger Polypeptide Gene at the Human Chromosome 11 Wilms' Tumor Locus,”Cell60: 509-520, 1990.
Carapeti et al., “Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia,”Eur. J. Haematol. 58: 346-349, 1997.
Charles et al., “Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: an immunohistochemical study,”J. Clin. Pathol.: Mol. Pathol. 50: 138-144, 1997.
Charles et al., “Immunohistochemical detection of the Wilms' tumour gene WT1 in desmoplastic small round cell tumour,”Histopathology30: 312-314, 1997.
Chen et al., “T-cells for tumor therapy can be obtained from antigen-loaded sponge implants,”Cancer Research54(4):1065-1070, Feb. 15, 1994.
Chesebro et al., “Characterization of Ia8 antigen, THY-1.2 antigen, complemnt receptors, and virus production in a group of murine virus-induced leukemia cell lines,”The Journal of Immunology117(4):1267-1274, Oct. 1976.
Crawford et al., “Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes,”Immunity8:675-682, Jun. 1998.
De Bruijn et al., “Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses,”Eur J Immunol21(12):2963-2970, Dec. 1991.
Deavin et al., “Statistical comparison of established T-cell eptiope predictors against a large database of human and murine antigens,”Molecular Immunology, 33(2):145-155, 1996.
Drummond et al., “Repression of the Insulin-Like Growth Factor Gene by the Wilms Tumor Suppressor WT1,”Science257: 674-677, 1992.
Feller and de la Cruz, “Tsites (Version 1.1) A computer program to determine T cell epitopes using four predictive algorithms,”Nature349: 720-721, 1991.
Foster et al., “Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model,”Cancer Research57(16):3325-3330, Aug. 15, 1997.
Frazier et al., “Expression of the Tumor Suppressor Gene WT1 in Both Human and Mouse Bone Marrow,”Blood86: 4704-4706, 1995 (letter).
Gaiger et al., “Immunity to WT1 in animal models and leukemia pateints,”Blood, 94(10):78, Nov. 15, 1999.
Gaiger et al., “Immunity to WT1 in the animal model and in patients with acute myeloid leukemia,”Blood96(4):1480-1489, Aug. 15, 2000.
Gaiger et al., “WT1: A new leukemia and cancer antigen A,”Proceedings of the Annual Meeting of the American Association for Cancer Research, 40:424, 1999.
Gillis and Smith, “Long term culture of tumour-specific cytotoxic T cells,”Nature268:154-156, Jul. 14, 1977.
Glynn et al., “Cross-resistance to the transplantation of syngeneic friend, moloney, and rauscher virus-induced tumors,”Cancer Research28(3):434-439, Mar. 1968.
Goodyer et al., “Repression of the retinoic acid receptor-α gene by the Wilms' tumor suppressor gene product, wt1,”Oncogene10: 1125-1129, 1995.
Haber et al., “A dominant mutation in the Wilms tumor geneWT1coop

Affiliated with

Also associated with

Rating

Compositions and methods for WT1 specific immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for WT1 specific immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for WT1 specific immunotherapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2704433